ANTI-SV2A CLONE 1I4 ZOOMAB RB MONO (C15-1670-139)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 1I4 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects Synaptic vesicle glycoprotein 2A (SV2A). It targets an epitope within 20 amino acids from the N-terminal, cytoplasmic domain.

Immunogen

KLH-conjugated linear peptide corresponding to 20 amino acids from the N-terminal, cytoplasmic domain of human Synaptic vesicle glycoprotein 2A (SV2A).

Application

Quality Control Testing

Evaluated by Western Blotting in SH-SY5Y cell lysate.

Western Blotting Analysis (WB): A 1:1,000 dilution of this antibody detected SV2A (Synaptic Vesicle Glycoprotein 2A) in SH-SY5Y cell lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected SV2A in human brain tissue lysate.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected SV2A in E18 cortical and SH-SY5Y cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected SV2A in human cerebral cortex and mouse hippocampus tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound SV2A peptides with a KD of 1.4 x 10-7 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-SV2A, clone 1I4 ZooMAb^®, Cat. No. ZRB1720, is a recombinant Rabbit monoclonal antibody that specifically targets SV2A and is tested for use in Affinity Binding Assay, Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Target description

Synaptic vesicle glycoprotein 2A (UniProt: Q7L0J3; also known as SV2A) is encoded by the SV2A (also known as KIAA0736, PSEC0174) gene (Gene ID: 9900) in human. SV2A is a multi-pass membrane glycoprotein with seven cytoplasmic domains, twelve transmembrane domains, and six extracellular domains. It plays a role in the control of regulated secretion in neural and endocrine cells, enhancing selectively low-frequency neurotransmission. It is also reported to positively regulate vesicle fusion by maintaining the readily releasable pool of secretory vesicles. SV2A is widely distributed in the nervous system and in endocrine tissue. It is enriched in chromaffin granules and associates with both insulin granules and synaptic-like microvesicles in insulin-secreting cells of the pancreas. SV2A interact with synaptotagmin-1 in a calcium-dependent manner and this interaction is highly controlled. Phosphorylation of SV2A by casein kinase I in the amino terminal region increases its affinity for synaptotagmin-1. Although its N-terminal has two phosphorylation clusters, only threonine 84 phosphorylation appears to be essential for binding and forms hydrogen bonds with three conserved lysine residues of the C2B domain of synpatotagmin-1. The correct folding of SV2A appears to be important for its function and proper location since many substitution mutations are reported to produce diffuse or aggregated cytoplasmic locations of SV2A. SV2A-knockout mice are reported to develop severe seizures within one postnatal week and death ensues within 2 to 3 weeks. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Bartholome, O., et al. (2017). Front. Mol. Neurosci. 10; 148).

Physical form

Purified recombinant mouse monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

30 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.